cidofovir

Key facts

Drug.verifiedrevid

477165826

Drug.IUPAC_name

({[(S)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid

Drug.image

Cidofovir.svg

Drug.image_class

skin-invert-image

Drug.width

225

Drug.tradename

Vistide

Drug.pregnancy_AU

D

Drug.routes_of_administration

Intravenous

Drug.ATC_prefix

J05

Drug.ATC_suffix

AB12

Drug.legal_AU

S4

Drug.legal_CA

Rx-only

Drug.legal_UK

POM

Drug.legal_US

Rx-only

Drug.bioavailability

complete

Drug.protein_bound

<6%

Drug.elimination_half life

2.6 hours (active metabolites: 15–65&nbsp;hours)

Drug.excretion

renal The above pharmacokinetic parameters are measured for cidofovir used in conjunction with probenecid.

via Wikipedia infobox

• Cidofovir.Drugs · 1996
• Cidofovir.Archives of ophthalmology (Chicago, Ill. : 1960) · 1997
• Cidofovir in the Management of Non-Genital Warts: A Review.Journal of drugs in dermatology : JDD · 2023
• Cidofovir.The AIDS reader · 1999
• Intralesional cidofovir vs. bevacizumab for recurrent respiratory papillomatosis: a systematic review and indirect meta-analysis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2024

via PubMed